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Abstract
Purpose The study aims to identify the occurrence and remis-
sion of statin-induced myopathy including patient perception
and symptom characteristics with a gender perspective.
Methods The study was designed as a prospective, non-
interventional investigation in 192 outpatients receiving statin
treatment in usual care with 12 months follow-up. Main out-
come measure was myopathy related to statin treatment and
classified as probable using WHO criteria for adverse drug
reaction (ADR) assessment.
Results Fourteen percent developed myopathy, risk ratio for
women 1.52 [95 % CI 1.37; 1.66] as compared to men. The
majority graded their pain as Bsevere.^ CK values were within
normal range. Eighty percent of the women compared to 43%
of the men reported that the muscular symptoms affected their
daily life activities to a moderate or severe extent. For those
who stopped treatment, mypopathy was the reason for 70% of
the women and 25 % of the men. There was a difference in
mean dose between men with and without myopathy, but not
in women. Among the patients with myopathy, 76 % reported
other ADRs as compared to 21 % of the patients without
myopathy (p = 0.002). Twenty-nine percent of the women
and 18 % of the men reported other ADRs.
Conclusion Women reported a higher frequency of myopathy
and other ADRs as well as a larger impact on daily life activ-
ities. In men, but not in women, the risk of myopathy was
dose-dependent. Patients with myopathy were more suscepti-
ble to other statin-induced ADRs which raises the question
about common underlying mechanisms.
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Introduction
HMG Co-A reductase inhibitors have proven to efficiently
lower serum concentration of low-density lipoprotein choles-
terol (LDL-C-C) and to reduce the risk of cardiovascular dis-
ease (CVD). Since their introduction in the mid-80s, the indi-
cation for using statins in clinical practice has been well-
established and few other drugs have been so widely used
for such a long time [1–6]. Generic statins remain a corner
stone in CVD prevention. New lipid modifying drugs such as
PCSK9 inhibitors are available but are not considered cost-
effective for the majority of patients [7]. The withdrawal of
cerivastatin in 2001 highlighted the ability of statins to cause
more or less severe myopathy including e.g., rhabdomyolysis.
Today, the frequency is considered to range from 5 [8, 9] to
15 % [10, 11] depending on definition of myopathy and study
design. Several studies have indicated that women seem to be
more susceptible for muscular adverse drug reactions (ADRs)
than men, especially elderly women. The reasons for these
differences are unknown. Little attention has been paid to
sex differences and myopathy [12]. In general, women were
underrepresented in early large scale randomized trials such as
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the 4S study (19 %), the CARE study (14 %), the LIPID study
(17 %), and more surprisingly also in more recent studies such
as the PROVE-IT study (22 %) [13–16]. The PRIMO study
and the JUPITER study included more women, 35 and 38 %,
respectively [17–21]. Regardless of the reported frequency of
ADRs, myopathy in routine care is a clinical dilemma and
could constitute a major reason for the poor adherence to statin
therapy that has been demonstrated in many studies [11,
22–24]. Statin treatment differs between women and men as
was recently shown by Ballo et al. who also demonstrated that
the benefits were equal if the same dose was used, but side
effects was not within the scope of this study [25].
In this study, we sought to investigate the statin use and
statin management in usual care with the gender disparities as
main focus. We sought to identify the occurrence and remis-
sion of myopathy and include patient perception and symptom
characteristics. Aware of the sensitive task to collect data on
muscular side effects without interfering with the patient’s
own perception, we chose a pragmatic study design, allowing
both patients that were statin naïve and patients that switched
the statin to be included. This design shortened our timelines
allowing the study team to follow naïve subjects Binto
myopathy^ and myopathy patients Bto remission^ during
12 months in usual care.
Methods
Study design
The study was designed as a prospective, non-interventional
investigation in outpatients receiving statin treatment during a
12 month period. It encompassed 192 patients from 20 sites
(primary care and cardiology outpatient clinics) in the
Stockholm County. Swedish speaking patients older than 18,
who in the opinion of their physician should start statin treat-
ment or switch to another statin, were included. No interven-
tion with the selection of patients or with statin management
was made. Patients were followed for 12 months with two or
three visits. Visits took place at start of the study, at 1–
3 months, 6–9 and at 9–12months thereafter. The first eligible
patient was included in June 2007, and last patient visit was in
December 2010.
Ethics
This study was approved by the Regional Ethics Committee in
Stockholm and the Swedish Medical Products Agency (MPA)
EudraCT 2006–00,486-34. The study complied with the
Declaration of Helsinki of The World Medical Association
and the International Conference of Harmonization
Guideline of Good Clinical Practice (ICH-GCP, E6).
Participants and clinical procedures
All participants signed an informed consent before the start
of the study. We used case report forms (paper or electron-
ic), patient questionnaires, and standardized interviews for
data capturing. Medical history included information on
previous and current CVD, other diseases and life style
factors e.g., smoking status, alcohol intake, and exercise.
Information on concomitant medication was collected and
categorized by ability to interact with CYP3A4 metabo-
lism. Physical examination included blood pressure, waist
circumference, bodyweight, and height. CVD risk classifi-
cation was performed according to Reiner et al. [26]. Blood
samples were analyzed for total plasma cholesterol (TPC),
low density lipoprotein cholesterol (LDL-C), high density
lipoprotein cholesterol (HDL-C), triglycerides (TG), apoli-
poprotein A1 and B, creatinine kinase (CK), myoglobulin,
creatinine, hs-CRP, thyroid stimulating hormone (TSH),
aspartate aminotransferase (AST), and alanine aminotrans-
ferase (ALT). Blood samples were analyzed at the
Karolinska University Laboratory.
Patient questionnaires and standardized interviews
The questionnaires covered muscular symptoms, other
symptoms known to be related to statin treatment, daily
life activities, statin compliance, educational level, life-
style factors, and VAS EQ-5D (quality of life instrument)
[27]. There were fixed response alternatives on muscle
symptoms and their impact on daily life activities on a
four-step categorical scale and on a numerical scale
(NRS, 1–10). For quality of life measurement, we used
EQ-5D self-rated VAS scale (graded 1–100) the two end-
points, labeled 1 = Bworst imaginable health^ and
100 = Bbest imaginable health.^
Definition of muscular adverse drug reaction
To define myopathy, we used the criteria of the American
College of Cardiology (ACC), American Heart Association
(AHA), and National Heart, Lung, and Blood institute
(NHLBI) [24]. The ADRs from muscles and the time to onset
were assessed only in the Bde novo treated^ patients. In the
Bswitch^ group, we assessed if muscular symptoms improved
after the statin switch. Time to onset was categorized as 0–90,
91–180, 181–270, or >270 days after start.
ADR evaluation
The endpoint evaluation of ADRs was based on physicians’
reports, patient questionnaires, and standardized telephone in-
terviews and reviews of patients’medical records. An increase
of two grades on the NRS and/or one step at the categorical
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scale was considered clinically relevant. Symptoms meeting
these criteria were assessed and classified as Bprobable^ or
Bpossible^ according to WHO, or neither Bprobable^ nor
Bpossible^ [28].
Other ADRs such as gastrointestinal symptoms or head-
ache are referred to as Bother ADRs, only the ones assessed
as ‘probable’^ were included. An increase of two grades on
the NRS and/or one step at the categorical scale was consid-
ered clinically relevant.
All patients who were eligible and who initiated statin treat-
ment or made a switch were included in the full analysis set and
are presented in Table 1. All patients included in the analysis
reported that they took their statin 5–7 days per week. Baseline
characteristics and data from primary endpoint analysis are pre-
sented for all patients who started with statin treatment and
continued to first follow-up. In the analysis of myopathy, only
de novo patients with a probable ADR were included.
Statistics Independent t test and Fisher’s test exact (two-
sided) were used to compare factors in the myopathy group
with the group without myopathy. The responses to daily life
activity (DLA) were dichotomized.
All results are expressed as means ± SD, or proportion/
percentages for parametric and non-parametric data, respec-
tively. All analyses and descriptive data were performed using
SPSS 22.0.
Equipotent doses
Simvastatin was the most widely used statin in Sweden
during the study period and was therefore used as a refer-
ence drug for equipotent doses (based on their ability to
lower LDL): simvastatin 5–10 mg = pravastatin 10–
20mg= fluvastatin 20–40mg. Simvastatin 20mg=pravastatin
40 mg = atorvastatin 5 mg. Simvastatin 40 mg = rosuvastatin
10 mg = atorvastatin 10 mg [29].
Results
Patient flow and patient characteristics at study start
One hundred ninety-two individuals were screened for study
participation whereof 12 subjects were assessed as screening
failures. Of the remaining 180 eligible individuals, 120 were
Bde novo^ patients and 60 Bswitch^ patients, whereof 49 and
50% females, respectively. Seventy-eight percent of the wom-
en completed the study and 86 % of the men. Of those who
pre-terminated the study, 70 % of the women and 25 % of the
men did so due to muscular symptoms.
At baseline, 35 % of the women and 58 % of the men stated
no muscular symptoms. Of the patients experiencing muscular
symptoms at study start (pain, weakness, soreness), 65 % of the
women and 42 % of the men described Bmild^ or Bmoderate^
problems with a mean pain score (NRS) 2.9 (SD 3.2) for
women and 1.9 (SD2.6) as Bmoderate^ (p = 0.01). No patient
described their muscular status as Bsevere^ at study start.
Patient characteristics are summarized in Table 1.
Statin treatment and myopathy in the de novo-treated
patients
In all, 17 patients (14 %) of the patients experienced myopa-
thy. Seventeen percent of the women and 12% of the men had
myopathy; all of which had myalgia. For women who started
statin treatment, the risk ratio (RR) was 1.52 [95 % CI 1.37;
1.66] for myopathy compared to men. There were no cases of
myositis or rhabdomyolysis. All patients had CK values with-
in the reference range throughout the study.
Twenty-six percent of the elderly (≥75 years) had myopathy
as compared to 14 % of the other patients, RR 1.84 [95 % CI
1.61; 2.06]. Given the limited number of elderly in the study, no
further analysis was made on the differences between these age
groups or the interaction between age and gender.
Table 1 Baseline demographic and disease characteristics
Patient characteristics at baseline Total (N = 180) Women (N = 89) Men (N = 91) p*
Age (years), mean (SD) 64.7 (10.4) 68.1 (8.9) 61.3 (10.6) 0.001
Age > 75 years, n (%) 33(18.3) 22 (24.7) 11 (12.1) 0.034
Low CVD risk, n (%) 8 (4.4) 3 (3.4) 5 (5.5) 0.720
Moderate CVD risk, n (%) 87 (48.3) 55 (61.8) 32 (35.2) 0.001
High CVD risk, n (%) 36 (20.0) 11 (12.4) 25 (27.5) 0.022
Very high CVD risk, n (%) 49 (27.2) 20 (22.5) 29 (31.9) 0.180
Muscular pain/soreness VAS score, mean (SD) 1.9 (2.2) 2.3 (2.36) 1.5 (2.0) 0.822
*Analysis for significance on continuous data level: independent t-sample test used. Levene’s test for equality of variances. Significance value two-tailed.
On categorical data on ordinal or nominal level, significance was analyzed with chi-squared test/Fishers exact test, using non-parametric Levene’s test
Additional patient characteristics at baseline are shown in Supplementary Table S1
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All patients with myopathy had been prescribed simvastat-
in, mean dose 25.3 mg (SD10.1) as compared to patients
without myopathy 22.4 mg (SD 8.7), p = 0.235. Women in
the myopathy group had a mean dose 21.0 mg (SD7.4) as
compared to 22.5 mg (SD8.6) for women without myopathy,
p = 0.626. The mean dose for men in the myopathy group was
31.4 mg (SD10.7), as compared to 23.7 mg (SD 9.4) for men
without myopathy, p = 0.017.
All patients but one (16/17) with myopathy noticed the
symptoms within the first month of statin treatment, and the
17th patient had symptoms shortly after a dose increase after
6 months of treatment.
Muscle pain increased with an average of 6.0 (SD 2.2)
on NRS, in women +5.3 points (SD 2.6), in men +7.0 (SD
2.5). The intensity of myopathy was graded as mild for
12 % (2/17) (50 % women), as moderate for 35 % (6/17)
(67 % women), and as severe for 53 % (9/17) (56 % wom-
en). Sixty-seven percent reported that the muscular symp-
toms affected their daily life activities to a Bmoderate or
severe^ extent, 80 % of the women (8/10), and 43 % (3/7)
of the men (p = 0.001).
Patients with both muscular pain and weakness reported
that their daily activities were affected to a greater extent than
patients with pain only.
Myopathy was more frequent among patients at Bvery
high CVD risk^ than the other CVD risk categories
(p = 0.048). There was no difference in other patient char-
acteristics such as body weight or renal function, see
Supplementary Table S2.
Sub-analysis of the de novo group
Among the patients with myopathy, 76 % reported other
ADRs as compared to 21 % of the patients without myopathy
(N = 103; p = 0.002). These ADRs were also noted during the
first follow up period. Twenty-three percent of the patients
reported 38 Bother ADRs^. Twenty-nine percent of the wom-
en and 18 % of the men reported at least one other ADR.
There were 16 reports of sleep disturbance, 15 of gastrointes-
tinal problems, and 5 reports of skin rash. Elevated liver
enzymes were observed in two patients.
The switch group
Among patients with muscular symptoms at study start in the
Bswitch^ group, the symptoms resolved within 3 months in 17
of 25 (68 %). These patients continued their statin treatment
throughout the study. In the other patients (32 %; all women),
the muscular symptoms persisted despite additional switches
and/or decreased statin dose. These patients discontinued stat-
in treatment before the study ended.
Discussion
In our study, we examined the frequency of myopathy among
women and men on statin treatment in usual care including its
time to onset and remission.We found that among all subjects,
14% experienced myopathy, 17% of the women, and 12% of
the men. All cases of myopathy were myalgia with CK levels
within normal range. This frequency of myalgia is consistent
with 13 % reported by Riphagen et al. [7]. However, in that
study, the assessment of the relation between myalgia and
statin treatment was made by the patients. Our results repre-
sent a cautious estimate of the myopathy frequency since we
included only cases assessed as at least probable.
As in several other studies, we also found that myopathy
was overrepresented among women and patients older than
75 years [20, 24, 30]. We had 50 % women in our study
population which reflect the gender distribution of the patients
who purchased statin prescription in Stockholm County dur-
ing this period. The study population did not fully reflect the
proportion of elderly among statin-treated patients in the re-
gion, 18 versus 28 % (The Swedish Prescribed Drug
Register). Information about the percentage of elderly in other
studies is not readily available, since most studies only report
mean age of the patients.
Statin myopathy is considered to be dose-dependent. We
also found a significant difference in mean dose between men
with and without myopathy, but between the women, there
was no difference. However, 20 % of the women in the my-
opathy group had a concomitant medication with a potential to
inhibit CYP3A4, thereby increasing the plasma concentration
of some statins. Even so, these findings point to the need to
better understand the mechanisms of statin-induced myalgia
in women and men, respectively.
The myopathy occurred within the first month of treatment,
as previously shown [20, 31]. There were no gender dispar-
ities in time to onset. However, men reported higher pain
intensity, and women reported greater impact on daily life
activities. The analysis also indicated that patients at very high
risk for CVD were 30 % more likely to experience myopathy
as compared to those with lower degrees of CVD risk. From a
public health perspective, it is a challenge if those who would
benefit the most from statin treatment would tolerate it the
least. The unsatisfactory low adherence during long-term ther-
apy, as has been demonstrated in several studies [32–34], may
have a two-folded background. It seems likely that early dis-
continuation is caused by myopathy and/or other ADRs, since
these symptoms usually occur within the first treatment
month. For the late discontinuers, other factors such as Black
of motivation^ to continue a risk modifying treatment could
play a bigger role. Therefore, the time slot for assessment of
long-term adherence is critical for the final estimate.
Of those already experiencing myopathy at the time of
inclusion, the symptoms resolved in 68 % of the patients after
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switch to another statin. A similar high percentage of success-
ful switches has been reported by Harris et al. [35]. Our sub-
analysis showed that the vast majority of patients with a my-
opathy also reported other statin-related ADRs, which raises
the question of common underlying mechanisms.
Further studies on common as well as gender specific
causes of myopathy and other ADRs are warranted to enable
an optimization of statin treatment to further improve the sec-
ondary prevention of CVD in women and men. Our study
suggests special considerations of the gender difference,
women appearing to have more side effects and larger impact
on daily life activities than men.
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